pubmed.ncbi.nlm.nih.gov

Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study - PubMed

Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study

M Thorogood et al. Br J Obstet Gynaecol. 1991 Dec.

Abstract

Objective: To investigate the association between fatal myocardial infarction and use of modern low-dose oral contraceptives.

Design: A case-control study.

Setting: General practices throughout England and Wales.

Subjects: 161 women aged under 40 dying from myocardial infarction during 1986-1988. Living controls (2 per case), matched for age and marital status, were chosen from general practice lists. Information was collected during structured interviews with general practitioners, and from postal questionnaires sent to surviving partners of the cases and to control women.

Main outcome measures: Mortality from myocardial infarction in relation to many risk factors, notably oral contraception, as measured by relative risk.

Results: After allowing for the confounding effects of medical risk factors and for surgical sterilization, the overall relative risk associated with both current and past use of oral contraceptives was estimated to be 1.9 (95% CI 0.7 to 4.9, and 1.0 to 3.5 respectively). The relative risk associated with current use of preparations containing 50 micrograms of oestrogen, however, was estimated to be 4.2 (0.5 to 39.2). At least some of the relative risk associated with oral contraceptive use is likely to be attributable to the confounding effect of cigarette smoking, but it is impossible to estimate how much from the available data.

Conclusions: If there was an increased risk of fatal myocardial infarction associated with oral contraceptive use in 1986-1988 it is likely to have been less than two-fold; in this study risks were slightly, but not significantly, elevated with both current and previous use. It may be that any increase in risk is associated solely with the older combined preparations containing 50 micrograms of oestrogen.

PubMed Disclaimer

Cited by

Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.
Godsland IF, Winkler U, Lidegaard O, Crook D. Godsland IF, et al. Drugs. 2000 Oct;60(4):721-869. doi: 10.2165/00003495-200060040-00003. Drugs. 2000. PMID: 11085198 Review.
Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status.
Potts M, Denny C. Potts M, et al. Drug Saf. 1995 Dec;13(6):333-7. doi: 10.2165/00002018-199513060-00002. Drug Saf. 1995. PMID: 8652077
Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis.
Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, Brown E, Chowdhury R, Muka T, Franco OH. Glisic M, et al. Eur J Prev Cardiol. 2018 Jul;25(10):1042-1052. doi: 10.1177/2047487318774847. Epub 2018 May 10. Eur J Prev Cardiol. 2018. PMID: 29745237 Free PMC article.
The combined oral contraceptive. Risks and adverse effects in perspective.
Bagshaw S. Bagshaw S. Drug Saf. 1995 Feb;12(2):91-6. doi: 10.2165/00002018-199512020-00002. Drug Saf. 1995. PMID: 7766340 Review.
Progestin-only contraception and thromboembolism: A systematic review.
Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Tepper NK, et al. Contraception. 2016 Dec;94(6):678-700. doi: 10.1016/j.contraception.2016.04.014. Epub 2016 May 3. Contraception. 2016. PMID: 27153743 Free PMC article. Review.

Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study - PubMed